How to Select a Local Agent for Medical Device Registration in Japan

Direct answer: Before selecting a local agent for medical device registration in Japan, a manufacturer should first confirm the target market, the risk class of the product, the applicable regulatory pathway and the current documentation base, and only then evaluate the technical file, quality system evidence, labelling and instructions for use (IFU), local agent arrangements, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, missing documents or undefined authorization arrangements do not extend the project timeline. For Chinese medical device manufacturers, the more reliable approach is to carry out product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Key points

Registration in a target market typically affects the technical file, authorized representative arrangements, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If a project is driven only by the question of which documents must be submitted, corrections and rework are likely to arise in model coverage, evidence chain consistency, label claims and control over certificates.

AIMEILI recommends placing this question within a broader GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets, rather than rebuilding documentation from scratch for each country.

Applicable scenarios and core questions

Companies asking how to select a local agent for medical device registration in Japan are usually not looking for a conceptual explanation. They need to determine whether their existing documentation can support an application in the target market, whether a local agent or authorized representative is required, why timelines are extended, and which issues may affect the launch plan. Such questions usually involve product classification, the registration pathway, the evidence chain, label localization and post-market maintenance responsibilities at the same time.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East or Latin America at the same time, answering the process for one country alone is not sufficient. A more valuable approach is to first prepare reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labelling, and then localize them according to each country's regulatory requirements.

Registration decision logic

A manufacturer should first confirm the intended use, mechanism of action, use environment, method and duration of body contact, sterility, whether the device is active, and whether it incorporates software or has IVD characteristics. Only then can the risk class and submission pathway be determined. Once the pathway is wrong, all downstream translation, notarization, authorization, testing and supplementary submissions will move in the wrong direction.

For a target market project, the applicant entity and the boundaries of local responsibility must also be clarified: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documentation. If these points are left vague in commercial contracts, control over the market may be affected later.

Documentation and evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or other applicable quality system evidence, the technical file, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labelling and IFU, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. IFU claims, the model coverage of test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. What regulators assess is whether the device is safe, effective and traceable for its intended use in the target market, not how many documents have been uploaded.

Common mistakes

• Treating registration as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.
• Translating NMPA documentation directly and submitting it without reorganizing the evidence according to the target market pathway.
• Having too many models and specifications while test reports, clinical evidence or labelling coverage is insufficient.
• Selecting a local agent purely on the basis of sales cooperation, without defining regulatory responsibility, certificate control and post-market maintenance duties.
• Inconsistent claims across labels, IFU, promotional materials and registration documentation, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, which duplicates work for each country and multiplies both cost and timeline.

Company preparation checklist

Before starting a project, manufacturers are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission has begun.

• Compile the target product list, the model and specification matrix and the intended use statement.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation and English IFU.
• Confirm the duties, fees, certificate control and exit mechanisms of the local agent or authorized representative.
• Establish a gap assessment table for the target country, specifying what must be retested, translated, notarized or supported by additional declarations.

AIMEILI perspective

AIMEILI advises manufacturers not to treat registration in a target market as a one-off document submission, but to manage it as an overseas market access programme. For companies entering multiple countries, building a clear core technical file and evidence matrix first and then converting it according to national requirements is usually faster and more robust than assembling documents country by country, and it also supports subsequent changes and certificate renewals.

From a project management perspective, three items should be controlled early: first, product classification and pathway determination; second, the consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. Unless these three items are clear, a project may still encounter repeated rounds of deficiency responses, agent communication and post-market maintenance issues, even if the documentation appears extensive.

Frequently asked follow-up questions

Can domestic documentation be used directly for registration in a target market?

Domestic documentation can serve as a basis, but it normally cannot be submitted as it stands. Manufacturers need to adjust the documentation structure, language, labelling, authorization documents and evidence chain in line with local regulatory requirements.

When is the best time to start a gap assessment?

It is advisable to start immediately after the target market and product list have been confirmed. The earlier the gap assessment is completed, the easier it is to arrange retesting, translation, label adjustments and agent selection in advance.

Why does local agent selection affect registration quality?

A local agent usually participates in regulatory communication, changes, certificate renewal and the handling of post-market events. Unclear duties and responsibilities can affect certificate control and the stability of the market after approval.

Project execution recommendations

When executing this type of registration project, manufacturers should set up a project register that manages the product list, model and specification matrix, registration pathway, document owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This makes documentation gaps visible early and helps management judge whether the project will affect the launch plan.

For companies that already hold registrations in several countries, an evidence reuse matrix should also be established, identifying which documents can serve as core evidence and which must be reissued or supported by supplementary explanations for each country. Labelling and IFU, clinical evaluation, risk management, performance verification and quality system certificates must in particular be kept version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Define the local agent and certificate control arrangements.
• Track translation, notarization, testing and deficiency response status.
• Assign post-market maintenance responsibilities in advance.

Quality system and evidence consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the device being submitted, or if the manufacturing site, model and specification matrix or IFU version is inconsistent with the test reports, additional explanations may be requested even when a large volume of documentation has been prepared.

Before submission, manufacturers should build an evidence consistency checklist mapping the product name, model and specification matrix, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and IFU version and quality system certificate item by item. This step appears basic, but it clearly reduces the likelihood of deficiency letters, and it is particularly relevant to projects submitted simultaneously in multiple GHWP member states or across several product families.

Localization and agent responsibilities

Registration projects in a target market usually involve a local agent, authorized representative, importer or registration holder arrangement. Manufacturers need to confirm in advance whether the local partner is only responsible for submitting documents or also for regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and the stability of the market after approval.

Labelling, IFU and authorization documents also cannot simply be translated. Manufacturers should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is to convert reusable evidence into a submission structure acceptable in the target country, rather than to write a separate, isolated set of documents.

Post-market maintenance and long-term planning

Registration approval does not mean that compliance work has ended. Manufacturers also need to maintain certificate validity periods, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance, so that a change of manufacturing site, expansion of models, IFU update or replacement of an agent later causes the certificate and market sales to fall out of step.

AIMEILI recommends managing this question within an annual international registration plan: first establish market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only greater efficiency in a single country; more importantly, it enables the manufacturer to build a repeatable overseas compliance capability and to reduce the cost of starting documentation from zero each time it enters a new market.

Further reading

Previous article: How is an ISO 13485 certificate used for medical device registration in Japan?

Next article: How are the responsibilities of an authorized representative for medical device registration in Japan divided?

Recommended reading:

• How should a local agent be selected for medical device registration in Brazil?
• How are the responsibilities of an authorized representative for medical device registration in Brazil divided?
• Why are registration timelines extended for medical device registration in Brazil?
• What are the common reasons for deficiency letters in medical device registration in Brazil?
• How should post-market surveillance be carried out for medical device registration in Brazil?
• When must a registration change be filed for medical device registration in Brazil?

Return to the FAQ Centre | News and information | Contact AIMEILI

Article information

Published: 2026-07-15 19:08; Updated: 2026-07-15 19:08.

This article reviews the questions manufacturers need to prioritise in real projects concerning international medical device registration, documentation preparation, compliance pathways and post-market maintenance.

Content review and applicability boundaries

Author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Applicability boundaries: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the regulatory authority in the target country, testing conclusions or legal advice. Specific projects should follow the latest requirements of the target country regulator and the actual documentation base of the device.